CBP target protein degrader (Foghorn Therapeutics)

N/A

Report date: 2025/03/19 08:59:39
NME

Base Information

Drug NameCBP target protein degrader (Foghorn Therapeutics)
Drug Alias NameTranscription activator SNF2L2 inhibitor (Foghorn Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActioncAMP-response element binding protein inhibitorsProbable global transcription activator SNF2L2 inhibitors
TargetscAMP-response element binding proteinProbable global transcription activator SNF2L2
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFoghorn Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFoghorn Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsLung NeoplasmsStomach Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A